- •Hematuria II: causes and investigation
- •Hematospermia
- •Lower urinary tract symptoms (LUTS)
- •Nocturia and nocturnal polyuria
- •Flank pain
- •Urinary incontinence in adults
- •Genital symptoms
- •Abdominal examination in urological disease
- •Digital rectal examination (DRE)
- •Lumps in the groin
- •Lumps in the scrotum
- •2 Urological investigations
- •Urine examination
- •Urine cytology
- •Radiological imaging of the urinary tract
- •Uses of plain abdominal radiography (KUB X-ray—kidneys, ureters, bladder)
- •Intravenous pyelography (IVP)
- •Other urological contrast studies
- •Computed tomography (CT) and magnetic resonance imaging (MRI)
- •Radioisotope imaging
- •Post-void residual urine volume measurement
- •3 Bladder outlet obstruction
- •Regulation of prostate growth and development of benign prostatic hyperplasia (BPH)
- •Pathophysiology and causes of bladder outlet obstruction (BOO) and BPH
- •Benign prostatic obstruction (BPO): symptoms and signs
- •Diagnostic tests in men with LUTS thought to be due to BPH
- •Why do men seek treatment for their symptoms?
- •Watchful waiting for uncomplicated BPH
- •Medical management of BPH: combination therapy
- •Medical management of BPH: alternative drug therapy
- •Minimally invasive management of BPH: surgical alternatives to TURP
- •Invasive surgical alternatives to TURP
- •TURP and open prostatectomy
- •Indications for and technique of urethral catheterization
- •Indications for and technique of suprapubic catheterization
- •Management of nocturia and nocturnal polyuria
- •High-pressure chronic retention (HPCR)
- •Bladder outlet obstruction and retention in women
- •Urethral stricture disease
- •4 Incontinence
- •Causes and pathophysiology
- •Evaluation
- •Treatment of sphincter weakness incontinence: injection therapy
- •Treatment of sphincter weakness incontinence: retropubic suspension
- •Treatment of sphincter weakness incontinence: pubovaginal slings
- •Overactive bladder: conventional treatment
- •Overactive bladder: options for failed conventional therapy
- •“Mixed” incontinence
- •Post-prostatectomy incontinence
- •Incontinence in the elderly patient
- •Urinary tract infection: microbiology
- •Lower urinary tract infection
- •Recurrent urinary tract infection
- •Urinary tract infection: treatment
- •Acute pyelonephritis
- •Pyonephrosis and perinephric abscess
- •Other forms of pyelonephritis
- •Chronic pyelonephritis
- •Septicemia and urosepsis
- •Fournier gangrene
- •Epididymitis and orchitis
- •Periurethral abscess
- •Prostatitis: presentation, evaluation, and treatment
- •Other prostate infections
- •Interstitial cystitis
- •Tuberculosis
- •Parasitic infections
- •HIV in urological surgery
- •6 Urological neoplasia
- •Pathology and molecular biology
- •Prostate cancer: epidemiology and etiology
- •Prostate cancer: incidence, prevalence, and mortality
- •Prostate cancer pathology: premalignant lesions
- •Counseling before prostate cancer screening
- •Prostate cancer: clinical presentation
- •PSA and prostate cancer
- •PSA derivatives: free-to-total ratio, density, and velocity
- •Prostate cancer: transrectal ultrasonography and biopsies
- •Prostate cancer staging
- •Prostate cancer grading
- •General principles of management of localized prostate cancer
- •Management of localized prostate cancer: watchful waiting and active surveillance
- •Management of localized prostate cancer: radical prostatectomy
- •Postoperative course after radical prostatectomy
- •Prostate cancer control with radical prostatectomy
- •Management of localized prostate cancer: radical external beam radiotherapy (EBRT)
- •Management of localized prostate cancer: brachytherapy (BT)
- •Management of localized and radiorecurrent prostate cancer: cryotherapy and HIFU
- •Management of locally advanced nonmetastatic prostate cancer (T3–4 N0M0)
- •Management of advanced prostate cancer: hormone therapy I
- •Management of advanced prostate cancer: hormone therapy II
- •Management of advanced prostate cancer: hormone therapy III
- •Management of advanced prostate cancer: androgen-independent/ castration-resistant disease
- •Palliative management of prostate cancer
- •Prostate cancer: prevention; complementary and alternative therapies
- •Bladder cancer: epidemiology and etiology
- •Bladder cancer: pathology and staging
- •Bladder cancer: presentation
- •Bladder cancer: diagnosis and staging
- •Muscle-invasive bladder cancer: surgical management of localized (pT2/3a) disease
- •Muscle-invasive bladder cancer: radical and palliative radiotherapy
- •Muscle-invasive bladder cancer: management of locally advanced and metastatic disease
- •Bladder cancer: urinary diversion after cystectomy
- •Transitional cell carcinoma (UC) of the renal pelvis and ureter
- •Radiological assessment of renal masses
- •Benign renal masses
- •Renal cell carcinoma: epidemiology and etiology
- •Renal cell carcinoma: pathology, staging, and prognosis
- •Renal cell carcinoma: presentation and investigations
- •Renal cell carcinoma: active surveillance
- •Renal cell carcinoma: surgical treatment I
- •Renal cell carcinoma: surgical treatment II
- •Renal cell carcinoma: management of metastatic disease
- •Testicular cancer: epidemiology and etiology
- •Testicular cancer: clinical presentation
- •Testicular cancer: serum markers
- •Testicular cancer: pathology and staging
- •Testicular cancer: prognostic staging system for metastatic germ cell cancer
- •Testicular cancer: management of non-seminomatous germ cell tumors (NSGCT)
- •Testicular cancer: management of seminoma, IGCN, and lymphoma
- •Penile neoplasia: benign, viral-related, and premalignant lesions
- •Penile cancer: epidemiology, risk factors, and pathology
- •Squamous cell carcinoma of the penis: clinical management
- •Carcinoma of the scrotum
- •Tumors of the testicular adnexa
- •Urethral cancer
- •Wilms tumor and neuroblastoma
- •7 Miscellaneous urological diseases of the kidney
- •Cystic renal disease: simple cysts
- •Cystic renal disease: calyceal diverticulum
- •Cystic renal disease: medullary sponge kidney (MSK)
- •Acquired renal cystic disease (ARCD)
- •Autosomal dominant (adult) polycystic kidney disease (ADPKD)
- •Ureteropelvic junction (UPJ) obstruction in adults
- •Anomalies of renal ascent and fusion: horseshoe kidney, pelvic kidney, malrotation
- •Renal duplications
- •8 Stone disease
- •Kidney stones: epidemiology
- •Kidney stones: types and predisposing factors
- •Kidney stones: mechanisms of formation
- •Evaluation of the stone former
- •Kidney stones: presentation and diagnosis
- •Kidney stone treatment options: watchful waiting
- •Stone fragmentation techniques: extracorporeal lithotripsy (ESWL)
- •Intracorporeal techniques of stone fragmentation (fragmentation within the body)
- •Kidney stone treatment: percutaneous nephrolithotomy (PCNL)
- •Kidney stones: open stone surgery
- •Kidney stones: medical therapy (dissolution therapy)
- •Ureteric stones: presentation
- •Ureteric stones: diagnostic radiological imaging
- •Ureteric stones: acute management
- •Ureteric stones: indications for intervention to relieve obstruction and/or remove the stone
- •Ureteric stone treatment
- •Treatment options for ureteric stones
- •Prevention of calcium oxalate stone formation
- •Bladder stones
- •Management of ureteric stones in pregnancy
- •Hydronephrosis
- •Management of ureteric strictures (other than UPJ obstruction)
- •Pathophysiology of urinary tract obstruction
- •Ureter innervation
- •10 Trauma to the urinary tract and other urological emergencies
- •Renal trauma: clinical and radiological assessment
- •Renal trauma: treatment
- •Ureteral injuries: mechanisms and diagnosis
- •Ureteral injuries: management
- •Bladder and urethral injuries associated with pelvic fractures
- •Bladder injuries
- •Posterior urethral injuries in males and urethral injuries in females
- •Anterior urethral injuries
- •Testicular injuries
- •Penile injuries
- •Torsion of the testis and testicular appendages
- •Paraphimosis
- •Malignant ureteral obstruction
- •Spinal cord and cauda equina compression
- •11 Infertility
- •Male reproductive physiology
- •Etiology and evaluation of male infertility
- •Lab investigation of male infertility
- •Oligospermia and azoospermia
- •Varicocele
- •Treatment options for male factor infertility
- •12 Disorders of erectile function, ejaculation, and seminal vesicles
- •Physiology of erection and ejaculation
- •Impotence: evaluation
- •Impotence: treatment
- •Retrograde ejaculation
- •Peyronie’s disease
- •Priapism
- •13 Neuropathic bladder
- •Innervation of the lower urinary tract (LUT)
- •Physiology of urine storage and micturition
- •Bladder and sphincter behavior in the patient with neurological disease
- •The neuropathic lower urinary tract: clinical consequences of storage and emptying problems
- •Bladder management techniques for the neuropathic patient
- •Catheters and sheaths and the neuropathic patient
- •Management of incontinence in the neuropathic patient
- •Management of recurrent urinary tract infections (UTIs) in the neuropathic patient
- •Management of hydronephrosis in the neuropathic patient
- •Bladder dysfunction in multiple sclerosis, in Parkinson disease, after stroke, and in other neurological disease
- •Neuromodulation in lower urinary tract dysfunction
- •14 Urological problems in pregnancy
- •Physiological and anatomical changes in the urinary tract
- •Urinary tract infection (UTI)
- •Hydronephrosis
- •15 Pediatric urology
- •Embryology: urinary tract
- •Undescended testes
- •Urinary tract infection (UTI)
- •Ectopic ureter
- •Ureterocele
- •Ureteropelvic junction (UPJ) obstruction
- •Hypospadias
- •Normal sexual differentiation
- •Abnormal sexual differentiation
- •Cystic kidney disease
- •Exstrophy
- •Epispadias
- •Posterior urethral valves
- •Non-neurogenic voiding dysfunction
- •Nocturnal enuresis
- •16 Urological surgery and equipment
- •Preparation of the patient for urological surgery
- •Antibiotic prophylaxis in urological surgery
- •Complications of surgery in general: DVT and PE
- •Fluid balance and management of shock in the surgical patient
- •Patient safety in the operating room
- •Transurethral resection (TUR) syndrome
- •Catheters and drains in urological surgery
- •Guide wires
- •JJ stents
- •Lasers in urological surgery
- •Diathermy
- •Sterilization of urological equipment
- •Telescopes and light sources in urological endoscopy
- •Consent: general principles
- •Cystoscopy
- •Transurethral resection of the prostate (TURP)
- •Transurethral resection of bladder tumor (TURBT)
- •Optical urethrotomy
- •Circumcision
- •Hydrocele and epididymal cyst removal
- •Nesbit procedure
- •Vasectomy and vasovasostomy
- •Orchiectomy
- •Urological incisions
- •JJ stent insertion
- •Nephrectomy and nephroureterectomy
- •Radical prostatectomy
- •Radical cystectomy
- •Ileal conduit
- •Percutaneous nephrolithotomy (PCNL)
- •Ureteroscopes and ureteroscopy
- •Pyeloplasty
- •Laparoscopic surgery
- •Endoscopic cystolitholapaxy and (open) cystolithotomy
- •Scrotal exploration for torsion and orchiopexy
- •17 Basic science of relevance to urological practice
- •Physiology of bladder and urethra
- •Renal anatomy: renal blood flow and renal function
- •Renal physiology: regulation of water balance
- •Renal physiology: regulation of sodium and potassium excretion
- •Renal physiology: acid–base balance
- •18 Urological eponyms
- •Index
Chapter 12 |
483 |
|
|
Disorders of erectile function, ejaculation, and seminal vesicles
Physiology of erection and ejaculation 484
Impotence: evaluation 488
Impotence: treatment 490
Retrograde ejaculation 492
Peyronie’s disease 494
Priapism 496
484 CHAPTER 12 Erectile function and ejaculation
Physiology of erection and ejaculation
Innervation
Autonomic
Autonomic sympathetic nerves originating from T11–L2, and parasympathetic nerves originating from S2–4 join to form the pelvic plexus. The cavernosal nerves are branches of pelvic plexus (i.e., parasympathetic) that innervate the penis.
Parasympathetic stimulation causes erection; sympathetic activity causes ejaculation and detumescence (loss of erection).
Somatic
Somatosensory (afferent) information travels via the dorsal penile and pudendal nerves and enters the spinal cord at S2–4. Onuf nucleus (segments S2–4) is the somatic center for efferent (i.e., somatomotor) innervation of the ischiocavernosus and bulbocavernosus muscles of the penis.
Central
The medial preoptic area (MPOA) and paraventricular nucleus (PVN) in the hypothalamus are important centers for sexual function and penile erection.
Mechanism of erection
Neuroendocrine signals from the brain, created by audiovisual or tactile stimuli, activate the autonomic nuclei of the spinal erection center (T11–L2 and S2–4). Signals are relayed via the cavernosal nerve to the erectile tissue of the corpora cavernosa, where nitric oxide (the principle neurotransmitter for penile erection) is released from nonadrenergic, noncholinergic (NANC) nerve terminals and from endothelium in the penis.
Cyclic GMP is then secondarily released via guanlyl cyclase, lowering intracellular calcium concentration within the endothelial cells, causing smooth muscle relaxation and increased arterial blood flow into the cavernosal sinuses of the penis.
A veno-occlusive mechanism (Table 12.1) is created by expansion of the sinusoidal spaces against the tunica albuginea, which compresses the subtunical venous plexuses, decreasing venous outflow and thus allowing “trapping” of blood within the erect penis. Maximal stretching of the tunica albuginea acts to compress the emissary veins that lie within its inner circular and outer longitudinal layers, reducing venous flow even further. Rising intracavernosal pressure and contraction of the ischiocavernosus muscles produces a rigid erection.
Following orgasm and ejaculation, vasoconstriction due to increased sympathetic activity and breakdown of cGMP via phophodiesterase type 5 produces detumescence (Figs. 12.1 and 12.2).
Ejaculation
Tactile stimulation of the penis causes sensory information to travel (via the pudendal nerve) to the lumbar spinal sympathetic nuclei. Sympathetic efferent signals (traveling in the hypogastric nerve) cause contraction of smooth muscle of the epididymis, vas deferens, and secretory glands, propelling spermatozoa and glandular secretions into the prostatic urethra.
PHYSIOLOGY OF ERECTION AND EJACULATION 485
There is simultaneous closure of the internal urethral sphincter and relaxation of the extrinsic sphincter, directing sperm into the bulbourethra (emission), but preventing sperm from entering the bladder. Rhythmic contraction of the bulbocavernosus muscle (somatomotor innervation) leads to the pulsatile emission of the ejaculate from the urethra.
During ejaculation, the alkaline prostatic secretion is discharged first, followed by spermatozoa and, finally, seminal vesicle secretions (ejaculate volume 2–5 mL). Ejaculatory latency of less than 2 minutes suggests a diagnosis of premature ejaculation.
Table 12.1 Phases of erectile process
Phase |
Term |
Description |
0 |
Flaccid phase |
Cavernosal smooth muscle contracted; |
|
|
sinusoids empty; minimal arterial flow |
1 |
Latent (filling) |
Increased pudendal artery flow; penile |
|
phase |
elongation |
2 |
Tumescent phase |
Rising intracavernosal pressure; erection |
|
|
forming |
3 |
Full erection |
Increased cavernosal pressure causes penis |
|
phase |
to become fully erect |
4 |
Rigid erection |
Further increases in pressure + |
|
phase |
ischiocavernosal muscle contraction |
5 |
Detumescence |
Following ejaculation, sympathetic discharge |
|
phase |
resumes; there is smooth muscle contraction |
|
|
and vasoconstriction; reduced arterial flow; |
|
|
blood is expelled from sinusoidal spaces |
|
|
|
Cavernosal smooth muscle
Nitric oxide (NO)
Vasoactive intestinal peptide Decrease in calcium RELAXATION (erection)
(VIP)
Prostaglandin E1 (PGE1)
Noradrenaline (NA) |
|
|
|
Increase in calcium |
CONTRACTION |
||
Endothelin-1 |
|||
(flaccidity) |
|||
Prostaglandin F2 (PGF2) |
|
||
|
|
||
|
|
Figure 12.1 Factors influencing cavernosal smooth muscle.
486 CHAPTER 12 Erectile function and ejaculation
|
L-citrulline |
|
|
||
L-arginine |
|
|
|
GTP |
|
|
|
|
|
|
|
NOS |
NO |
|
|
Guanylate cyclase |
PDE5 |
|
|||||
|
|
|
|
|
cGMP 5GMP
Cavernosal smooth muscle relaxation
ERECTION
VIP + PGE1
ATP |
|
|
cAMP |
|
Intracellular Ca2+ |
|
|
|
|||
|
|||||
|
|
|
Adenylate cyclase
Cavernosal smooth muscle relaxation
ERECTION
Figure 12.2 Secondary messenger pathways involved in erection.
This page intentionally left blank